Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).[4][5][6]
Common side effects include nasopharyngitis (cold), influenza-like illness, dizziness, rhinorrhea (runny nose), and nausea. Serious hypersensitivity (allergic) reactions have occurred in the Evkeeza clinical trials.[5]
Evinacumab binds to the angiopoietin-like protein 3 (ANGPTL3).[5] ANGPTL3 slows the function of certain enzymes that break down fats in the body.[5] Evinacumab blocks ANGPTL3, allowing faster break down of fats that lead to high cholesterol.[5] Evinacumab was approved for medical use in the United States in February 2021.[5][9][10] The U.S. Food and Drug Administration considers it to be a first-in-class medication.[11]
^"Details for: Evkeeza". Health Canada. 21 November 2023. Retrieved 3 March 2024.
^"Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22]". Health Canada. 22 December 2023. Retrieved 3 January 2024.
^"Summary Basis of Decision (SBD) for Evkeeza". Health Canada. 8 February 2024. Retrieved 24 February 2024.
^ abcdefg"FDA approves add-on therapy for patients with genetic form of severely". U.S. Food and Drug Administration (FDA). 11 February 2021. Retrieved 12 February 2021. This article incorporates text from this source, which is in the public domain.
^ ab"Drug Trial Snapshot: Evkeeza". U.S. Food and Drug Administration. 22 November 2022. Retrieved 23 November 2022. This article incorporates text from this source, which is in the public domain.
^Cite error: The named reference Evkeeza EPAR was invoked but never defined (see the help page).
^"Evkeeza Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^"FDA Approves First-in-class Evkeeza (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol" (Press release). Regeneron Pharmaceuticals. 11 February 2021. Retrieved 12 February 2021 – via PR Newswire.
^"Drug Approval Package: Evkeeza". U.S. Food and Drug Administration (FDA). 11 March 2021. Retrieved 13 September 2021.
^Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH)...
trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. The company also has therapies...
Global Information
This article incorporates text from this source, which is in the public domain.
